Regeneron Pharmaceuticals Inc REGN

NASDAQ US Health Care Biotechnology

$788.04 ▼ -1.00% ($-7.98)

Index member: S&P 500

⬇️ Below Yest. Low

Open $803.87

Prev Close $796.02

Day Range $784.13 – $803.87

52W Range $541.00 – $859.34

Market Cap $81.28B

P/E (TTM) 18.78

Beta 0.13

EPS (TTM) $40.45

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-04-02
Shares Out.	104,840,000
Website	regeneron.com/ ↗
Phone	17813705000
Employees	15,410
Revenue	$4.29B
Gross Profit	$3.71B
Net Income	$1.30B
Free Cash Flow	$3.76B
Total Assets	$41.73B
Total Liabilities	$10.02B
Equity	$31.71B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Regeneron Pharmaceuticals Inc is a publicly traded company under the ticker symbol REGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.